Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4 + T cells

Journal of Experimental Medicine

Volumn 200, Issue 6, 2004, Pages 701-712

  Lichterfeld, Mathias ^a   Kaufmann, Daniel E ^a   Yu, Xu G ^a   Mui, Stanley K ^a   Addo, Marylyn M ^a   Johnston, Mary N ^a   Cohen, Daniel ^b   Robbins, Gregory K ^a   Pae, Eunice ^b   Alter, Galit ^a   Wurcel, Alysse ^a,c   Stone, David ^c   Rosenberg, Eric S ^a   Walker, Bruce D ^a,d   Altfeld, Marcus ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Fenway Community Health Care Center   (United States)

^c LEMUEL SHATTUCK HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

CD4+ T cells; CD8+ T cells; HIV 1; Protective immunity; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; NEUTRALIZING ANTIBODY;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HLA TYPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; SUPPRESSOR CELL; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACUTE DISEASE; ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA;

EID: 4644249757     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041270     Document Type: Article

References (32)

1. Kahn, J.O., and B.D. Walker. 1998. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339:33-39.
2. Borrow, P., H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103-6110.
3. Koup, R.A., J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D.D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
4. Altfeld, M., E.S. Rosenberg, R. Shankarappa, J.S. Mukherjee, F.M. Hecht, R.L. Eldridge, M.M. Addo, S.H. Poon, M.N. Phillips, G.K. Robbins, et al. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med., 193:169-180.
5. Dalod, M., M. Dupuis, J.C. Deschemin, C. Goujard, C. Deveau, L. Meyer, N. Ngo, C. Rouzioux, J.G. Guillet, J.F. Delfraissy, et al. 1999. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Invest. 104: 1431-1439.
6. + T cells in primary HIV-1 infection. J. Virol. 77:6867-6878.
7. Addo, M.M., X.G. Yu, A. Rathod, D. Cohen, R.L. Eldridge, D. Strick, M.N. Johnston, C. Corcoran, A.G. Wurcel, C.A. Fitzpatrick, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-2092.
8. Draenert, R., C.L. Verrill, Y. Tang, T.M. Allen, A.G. Wurcel, M. Boczanowski, A. Lechner, A.Y. Kim, T. Suscovich, N.V. Brown, et al. 2004. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 78:630-641.
9. Betts, M.R., D.R. Ambrozak, D.C. Douek, S. Bonhoeffer, J.M. Brenchley, J.P. Casazza, R.A. Koup, and L.J. Picker. 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991.
10. Migueles, S.A., A.C. Laborico, W.L. Shupert, M.S. Sabbaghian, R. Rabin, C.W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
11. Rosenberg, E.S., M. Altfeld, S.H. Poon, M.N. Phillips, B.M. Wilkes, R.L. Eldridge, G.K. Robbins, R.T. D'Aquila, P.J. Goulder, and B.D. Walker. 2000. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:523-526.
12. Rosenberg, E.S., J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P.E. Sax, S.A. Kalams, and B.D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1447-1450.
13. + T cells endowed with proliferative capacity. J. Exp. Med. 198:1909-1922.
14. Robbins, G.K., M.M. Addo, H. Troung, A. Rathod, K. Habeeb, B. Davis, H. Heller, N. Basgoz, B.D. Walker, and E.S. Rosenberg. 2003. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 17:1121-1126.
15. Brander, C., and P. Goulder. 2000. The evolving field of HIV CRL epitope mapping: new approaches for the identification of novel epitopes. In HIV Molecular Database. B.T.M. Korber, C. Brander, B.D. Walker, R.A. Koup, J. Moore, B. Haynes, and G. Meyer, editors. Los Alamos National Laboratory. Los Alamos, New Mexico. 11-120.
16. Sidney, J., S. Southwood, C. Oseroff, M.-F. Del Guercio, and A. Sette. 1998. Measurement of MHC/peptide interactions by gel filtration. Curr. Prot. Immunol. 18:18.3.2-18.3.19.
17. Altfeld, M., M.M. Addo, R.L. Eldridge, X.G. Yu, S. Thomas, A. Khatri, D. Strick, M.N. Phillips, G.B. Cohen, S.A. Islam, et al. 2001. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167:2743-2752.
18. Alter, G., G. Hatzakis, C.M. Tsoukas, K. Pelley, D. Rouleau, R. LeBlanc, J.G. Baril, H. Dion, E. Lefebvre, R. Thomas, et al. 2003. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J. Immunol. 171:477-488.
19. Lacabaratz-Porret, C., A. Urrutia, J.M. Doisne, C. Goujard, C. Deveau, M. Dalod, L. Meyer, C. Rouzioux, J.F. Delfraissy, A. Venet, and M. Sinet. 2003. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J. Infect. Dis. 187:748-757.
20. Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 103:966-972.
21. Iyasere, C., J.C. Tilton, A.J. Johnson, S. Younes, B. Yassine-Diab, R.P. Sekaly, W.W. Kwok, S.A. Migueles, A.C. Laborico, W.L. Shupert, et al. 2003. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77:10900-10909.
22. Moss, R.B., C. Brandt, W.K. Giermakowska, J.R. Savary, G. Theofan, M. Zanetti, D.J. Carlo, and M.R. Wallace. 2003. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine. 21:1066-1071.
23. Moss, R.B., E. Webb, W.K. Giermakowska, F.C. Jensen, J.R. Savary, M.R. Wallace, and D.J. Carlo. 2000. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J. Acquir. Immune Defic. Syndr. 24:264-269.
24. Moss, R.B., M.R. Wallace, P. Lanza, W. Giermakowska, F.C. Jensen, G. Theofan, C. Chamberlin, S.P. Richieri, and D.J. Carlo. 1998. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin. Diagn. Lab. Immunol. 5:308-312.
25. Moss, R.B., W.K. Giermakowska, M.R. Wallace, J.R. Savary, F.C. Jensen, and D.J. Carlo. 2000. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen. AIDS. 14:2475-2478.
26. Turner, J.L., R.J. Trauger, A.E. Daigle, and D.J. Carlo. 1994. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS. 8:1429-1435.
27. Schmitz, J.E., M.J. Kuroda, S. Santra, V.G. Sasseville, M.A. Simon, M.A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B.J. Scallon, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:857-860.
28. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
29. Paiardini, M., D. Galati, B. Cervasi, G. Cannavo, L. Galluzzi, M. Montroni, D. Guetard, M. Magnani, G. Piedimonte, and G. Silvestri. 2001. Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals. J. Virol. 75:10843-10855.
30. Shankar, P., M. Russo, B. Harnisch, M. Patterson, P. Skolnik, and J. Lieberman. 2000. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood. 96:3094-3101.
31. The AIDS Clinical Trials Group 248 Study Team. 2004. Daily low-dose subcutaneous interleukin-2 added to singleor dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J. Acquir. Immune Defic. Syndr. 36:576-587.
32. Dybul, M., B. Hidalgo, T.W. Chun, M. Belson, S.A. Migueles, J.S. Justement, B. Herpin, C. Perry, C.W. Hallahan, R.T. Davey, et al. 2002. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185:61-68.